Within the MAPK pathway, the BRAFV600E mutation is found in 57% of ameloblastomas, while within the SHH pathway, Smoothened (SMO) mutations have been identified in 24% of ameloblastomas [6,29]. This evidence concerns the gene SMO and ameloblastoma.